Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Valeant execs outline development plans for taribavirin for hepatitis C, licensing opportunities and goals for ramping up the commercial organization ahead of potential new launches.